Open Orphan Investor Presentation March 2022 (Video)

Open Orphan plc (LON:ORPH) CEO Yamin ‘Mo’ Khan talks through its March 2022 Investor Presentation.

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.
For all the latest Open Orphan share price, news and interviews take a look at the company profile page.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

The History of Flu

Flu & Influenza The history of the flu dates to as far as humankind. Familiar symptoms of the flu were first recorded around 400BC by Hippocrates, a Turkish seasonal winter to spring respiratory ailment that resulted in coughs,

Open Orphan Plc

The lowdown on hay fever

Allergic rhinitis or, as it is commonly known, hay fever, is a reaction to allergens in the air. Most commonly this is a reaction to the pollen count, but can also be to dust, mould or pet hair.

Open Orphan Plc

Open Orphan subsidiary signs deal with global pharma company

Contract research company Open Orphan said its subsidiary hVivo has signed a deal with a major pharmaceutical client to manufacture a virus for use in human challenge studies. The unnamed client is a top five global company, Open Orphan said.

Open Orphan Plc

What is a Human Challenge Study?

During a human challenge study, a small number of healthy volunteers will receive a vaccine or drug which will be used to fight viruses. Volunteers are quarantined in our bespoke facilities in Whitechapel. We expose our volunteers to

Open Orphan Plc

Open Orphan appoint Liberum as its Nominated Adviser and Joint Broker

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that further to the announcements by Arden Partners Plc on

Open Orphan Plc

CMC regulatory team capabilities

For 20+ years, members of the CMC regulatory team supported several (bio)pharmaceutical companies to ensure manufacture of safe, effective, and high-quality drug products for patients globally. The support includes: Independent, trusted advice on your regulatory activities for each

Open Orphan Plc

How to build up your child’s immune system

Our Top 7 Tips to Boots Your Child’s Immune System Protecting your children from germs, bacteria and illnesses is a common concern for parents. Flu, colds, viruses and infections can cause misery for both you and your family

Open Orphan Plc

Open Orphan’s hVIVO presenting at the World Vaccine Congress

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, a subsidiary of

Open Orphan Plc

Hay fever season is back with a vengeance

Hay Fever is back! As the most common form of non-infectious rhinitis, hay fever affects 10-30% of adults and up to 40% of children. Hay fever season typically starts in mid-March as trees bloom until May. While this

Open Orphan Plc

Strategies for Non-clinical safety assessment of vaccines

Setting the scene Over the past century, vaccines have made a large impact on public health, as recently demonstrated by the treatment of the worldwide Covid-pandemic. Since, in general, vaccines are administered to healthy individuals, including infants and

Open Orphan Plc

Open Orphan’s hVIVO signs €6m contract for respiratory study

Dublin-listed clinical trials group Open Orphan has announced that its subsidiary Hvivo has signed a £5 million (€6m) human challenge study contract with a European biotechnology company. The study will test the company’s intravenous antiviral candidate for respiratory syncytial virus, the main

Open Orphan Plc

Open Orphan opens two new testing facilities

Specialist pharmaceutical services clinical research company Open Orphan is opening a new primary FluCamp volunteer recruitment screening facility in London and a secondary FluCamp recruitment facility in Manchester. Open Orphan tests vaccines and antivirals using human challenge clinical

No more posts to show